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Effects of human growth hormone on gonadotropin-
releasing hormone neurons in mice
Purpose: Recombinant human growth hormone (rhGH) has been 
widely used to treat short stature. However, there are some concerns 
that growth hormone treatment may induce skeletal maturation and   
early onset of puberty. In this study, we investigated whether rhGH 
can directly affect the neuronal activities of of gonadotropin-releasing 
hormone (GnRH). 
Methods: We performed brain slice gramicidin-perforated current 
clamp recording to examine the direct membrane effects of rhGH on 
GnRH neurons, and a whole-cell voltage-clamp recording to examine 
the effects of rhGH on spontaneous postsynaptic events and holding 
currents in immature (postnatal days 13-21) and adult (postnatal days 
42-73) mice.
Results: In immature mice, all 5 GnRH neurons recorded in 
gramicidin-perforated current clamp mode showed no membrane 
potential changes on application of rhGH (0.4, 1 μg/mL). In adult 
GnRH neurons, 7 (78%) of 9 neurons tested showed no response to 
rhGH (0.2-1 μg/mL) and 2 neurons showed slight depolarization. In 
9 (90%) of 10 immature neurons tested, rhGH did not induce any 
membrane holding current changes or spontaneous postsynaptic 
currents (sPSCs). There was no change in sPSCs and holding current in 
4 of 5 adult GnRH neurons.
Conclusion: These findings demonstrate that rhGH does not directly 
affect the GnRH neuronal activities in our experimental model.
Key words: Gonadotropin-releasing hormone, Growth hormone, 
Patch clamp technique
Janardhan P. Bhattarai, M.S.
1, Shin Hye Kim, 
M.D.
2, Seong Kyu Han, Ph.D.
1, and Mi Jung 
Park, M.D.
2
Department of Oral Physiology & Institute of Oral 
Bioscience
1, School of Dentistry, Chonbuk National 
University
Department of Pediatrics
2, Sanggye Paik Hospital, Inje 
University College of Medicine, Seoul, Korea
Received: 4 May 2010, Revised: 13 July, 2010
Accepted: 10 August 2010
Co-corresponding author: Mi Jung Park, M.D.
Department of Pediatrics, Sanggye Paik Hospital, Inje 
University College of Medicine, 761-1, Sanggye 7-dong, 
Nowon-gu, Seoul 139-707, Korea
Tel: +82.2-950-1075, Fax: +82.2-951-1246
E-mail: PMJ@paik.ac.kr
Co-corresponding author: Seong Kyu Han, Ph.D.
Department of Oral Physiology & Institute of Oral Bio-
science, School of Dentistry, Chonbuk National University, 
634-18, Keuman-dong, Dukjin-gu, Jeonju 561-756, Korea 
Tel: +82.63-270-4030, Fax: +82.63-270-4004
E-mail: skhan@jbnu.ac.kr 
Copyright © 2010 by The Korean Pediatric Society
Introduction
The use of recombinant human growth hormone (rhGH) has 
been increased in a variety of conditions associated with short 
stature, such as growth hormone deficiency, Turner syndrome, 
chronic renal failure, Prader-Willi syndrome, sustained postnatal 
growth failure in children who have been small for gestational age, 
and idiopathic short stature
1, 2). Many studies have shown that the 
administration of rhGH increases height
2-5). However, there are 
some concerns that growth hormone (GH) treatment may induce 
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skeletal maturation and an early onset of puberty. Randomized 
controlled studies for rhGH treatment of patients with idiopathic 
short stature have yielded differing results regarding the influence 
of GH on pubertal onset, pubertal pace, and bone maturation. 
Some authors demonstrated there was no effect on pubertal onset 
or pace in boys and girls
6, 7), while others demonstrated there was an 
acceleration of pubertal onset and bone maturation
8, 9). 
There are data to support the role of GH in the control of 
reproductive functions and the initiation of puberty. The suppression 
of GH secretion in female rats has been shown to delay puberty
10). 
In male rats, the experimental induction of GH deficiency is 
associated with the delay in testicular growth and the differentiation 
of the germ cells
11), suggesting a role for GH in the induction of 
puberty. The puberty onset in the GH receptor gene disrupted mice 
as determined by the age at vaginal opening was delayed
12). Plasma 
LH response to GnRH treatment was significantly attenuated 
in GH receptor gene knockout mice
13). However, the majority 
of the physiologic effects of GH on puberty has been explained 
by action of IGF-I. Patients with Laron syndrome are infertile, 
and administration of IGF-I initiates puberty in these subjects
14). 
Infusion of IGF-I has been shown to stimulate GnRH release 
from the median eminence and accelerate the onset of puberty in 
female rats
15, 16). Zhen et al.
17) demonstrated the expression of IGF-I 
receptors on GnRH neuronal cell line, and activation of GnRH 
mRNA expression and GnRH neuronal cell proliferation by 
IGF-I treatment. Although there are few studies suggesting GnRH 
neurons are activated by IGF-I, the direct effect of GH on GnRH 
neurons remains to be defined. In this study, we tried to elucidate 
the effect of rhGH on immature and adult GnRH neurons. 
Material and methods
1. Experimental animals
All experiments were approved by Chonbuk National University 
Animal Welfare and Ethics Committee. GnRH-green fluorescent 
protein tagged mice (Transgenic GnRH-EGFP-mut5) were 
housed under 12-h light, 12-h dark cycles (lights on at 07.00 h) 
with ad libitum access to food and water
18). Fifteen immature mice 
(postnatal day 13 to 21) and 14 adult mice (postnatal day 42 to 73) 
were used.
2. Brain slice preparation
Patch-clamp recordings were obtained in acutely prepared coronal 
slices as previously described
19). Mice were decapitated and brains 
were rapidly removed and placed in ice-cold bicarbonate-buffered 
artificial cerebrospinal fluid (ACSF) of the following composition (in 
mM): 126 NaCl, 2.5 KCl, 2.4 CaCl2, 1.2 MgCl2, 11 D-glucose, 1.4 
NaH2PO4 and 25 NaHCO3 (pH 7.3-7.4 when bubbled with 95% 
O2 and 5% CO2). Brains were blocked and glued with cyanoacrylate 
to the chilled stage of a vibratome (Microme, Walldorf, Germany), 
and 150 to 250 µ m-thick coronal slices containing rostral preoptic 
area were cut. The slices were allowed to recover in oxygenated 
ACSF for at least 1 hour at room temperature.
3. Chemicals
Recombinant humane growth hormone (Eutropin
®) was 
provided by LG Life Science, Ltd., and chemicals for ACSF and 
somatostatin were purchased from Sigma (USA). Applied reagents 
were dissolved in the ACSF solution and were diluted by 1,000 in 
perfused ACSF before use. The rhGH concentrations of ACSF 
solution were 0.2 µ g/mL, 0.4 µ g/mL and 1 µ g/mL respectively 
based on the previous studies
20-22). 
4. Electrophysiology and data analysis
The coronal slices were transferred to the recording chamber, 
held submerged, and continuously superfused with carboxygenated 
ACSF at a rate of 4-5 ml/min. The slices were viewed with an 
upright microscope (BX51WI; Olympus, Tokyo, Japan) and 
fluorescent GnRH neurons identified at 10X and 40X objective 
magnification by brief fluorescence illumination and then viewed 
and patched under Nomarski differential interference contrast 
optics. Patch pipettes were pulled from thin-wall borosilicate glass-
capillary tubing (PG52151-4, WPI, Sarasota, USA) on a Flaming/
Brown puller (P-97; Sutter Instruments Co., Novato, CA).  The 
pipette solution was passed through a disposable 0.22 µ m filter 
and contained (in mM): 140 KCl, 1 CaCl2, 1 MgCl2, 10 HEPES, 
4 MgATP, and 10 EGTA (pH 7.3 with KOH) for the whole-
cell experiment. The whole-cell patch-clamp recordings were 
were performed under voltage clamp using an Axopatch 200B 
(Axon Instruments, Union City, CA). The tip resistance of the 
electrode was 4-6 MΩ. The cells were voltage clamped at -60 mV 
after nullifying the potential between the patch pipette and bath 
solution. After a giga-seal, the membrane was ruptured by applying 
a slight negative suction. Membrane current changes were sampled 
online using a Digidata 1322A interface (Axon Instruments, USA) 
connected to an IBM PC. Any GnRH neurons that displayed a 
shift in holding current of >5 pA were considered to have responded. 
For perforated patch-clamp recording, a pipette solution containing 
(in mM): 130 KCl, 5 NaCl, 0.4 CaCl2, 1 MgCl2, 10 HEPES, and 
1.1 EGTA (pH 7.3 with KOH) was used. Gramicidin (Sigma, 
St. Louis, USA) was first dissolved in dimethylsulfoxide (Sigma) 
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solution just before use to a final concentration of 2.5-5 µ g/mL and 
sonicated for 10 minutes. In initial experiments, access resistance 
was monitored and experiments were begun when resistance 
stabilized at 50-90 MΩ. This typically took 15-20 minutes after 
giga-seal formation and always corresponded to the resting 
membrane potential (RMP) of the cell reaching a stable level below 
-45 mV. Spontaneous rupture of the membrane was evident by a 
sudden overshooting of action potentials above 0 mV. Acquisition 
and subsequent analysis of the acquired data were performed using 
the Clampex9 software (Axon Instruments, USA). Spontaneous 
postsynaptic currents (sPSCs, recorded at -60 mV), were detected 
and analyzed using Minianalysis (Synaptosoft). To assess the effects 
of rhGH on amplitude and frequency, the traces were measured 
and analyzed in 3-minute epochs using algorithms provided by 
Mini Analysis software. Traces were plotted using Origin7 software 
(Micro Cal Software, Northampton, MA). All recordings were 
made at room temperature.
5. Statistics 
All values were expressed as mean (SEM). The student Wilcoxon 
rank sum test was used to compare the means of 2 experimental 
groups. The Kruskal-Wallis test was performed to compare the 
membrane potential changes, and resting membrane potential 
(RMP), as well as the frequency and amplitude between more than 2 
experimental groups (SPSS Ver12). A level of P<0.05 was considered 
to be significant. 
Results
Electrophysiological recordings were obtained from a total of 29 
GnRH neurons. Fourteen neurons were recorded in gramicidin-
perforated patch-clamp mode, and the other 15 neurons were 
recorded in whole-cell voltage clamp mode at a holding potential 
of -60 mV (Table 1). Under gramicidin-perforated patch, the mean 
RMP was -61.5± 2.14 mV (n=14).
In gramicidin-perforated patch-clamp mode, none of the 5 
immature GnRH neurons (mean RMP = -59.2±4.71 mV) showed 
Table 1. Summary of Responses to rhGH of GnRH neurons in Perforated 













































































Note: The sum of numbers in the table may differ from the actual number of 
recorded GnRH neurons because some neurons were applied repeatedly by 
increasing concentrations. 
Fig. 1. rhGH-induced membrane depolarization in a minority of GnRH 
neurons only in adult. (A) Gramicidin-perforated patch recording 
of GnRH neuron (PND21) showing no response to applied rhGH (1 
μM). (B) Gramicidin-perforated patch recording from an adult GnRH 
neuron showing no response to applied rhGH (PND53). (C) Gramicidin-
perforated patch recording from adult showing sustained depolarization 
by rhGH (PND53). Dotted line indicates base line. (D) Application of 
300 nM somatostatin induced membrane hyperpolarization on a GnRH 
neuron (PND18). Abbreviations: rhGH, recombinant human growth 
hormone; GnRH, gonadotropin-releasing hormone; SST, somatostatin; 
PND, postnatal day.848      JP Bhattarai, et al. • Patch clamp study of rhGH on GnRH neurons
response to applied rhGH (0.4, 1 µ g/mL) (Fig. 1A). In adult GnRH 
neurons, 7 (78%, RMP = -60.2±2.59 mV) of 9 neurons showed no 
response to applied rhGH (0.2-1 µ g/mL) (Fig. 1B) and 2 neurons 
showed weak prolonged membrane depolarization (Fig. 1C) 
(3.79±0.68 mV n=2, 14.3%).
We tested somatostatin (SST), a known neuromodulator peptide 
in the central nervous system which suppresses the release of growth 
hormone (GH) as an opposite control. When SST was applied in 
the same cell tested with rhGH, SST induced the clear and potent 
membrane hyperpolarization (Fig. 1D) suggesting SST may 
directly act on GnRH neurons and can suppress their activities. 
In order to clarify whether the application of rhGH produces 
any change on postsynaptic current and holding current, 15 
GnRH neurons were tested with rhGH (0.2-1 µ g/mL) in voltage-
clamp mode with a holding potential of -60 mV (Table 1). Four 
out of 5 neurons from adult mice showed no changes in holding 
current and postsynaptic activities with the influence of rhGH. 
Nine (90%) of 10 immature neurons showed no response to rhGH 
(Fig. 2A). Among 15 neurons, 8 neurons were tested for the dose 
dependent effect, a concentration ranging from (0.2-1 µ g/mL) was 
applied, and none of them showed any change in synaptic events 
and holding current. Further postsynaptic currents were truncated 
to better depict changes in amplitude (Fig. 2B) and inter event 
intervals (IEE) (Fig. 2C). The rhGH did not shift the cumulative 
distribution histogram trace in any circumstances suggesting no 
change in amplitude and inter event interval upon application of 
rhGH. The amplitude and the frequency have shown no changes 
on application of rhGH (Fig. 2D, 2E). Five of 8 neurons applied 
with SST (300 nM) induced an outward current (15.8±0.52 pA) 
(Fig. 2F); however, the other 3 neurons showed no response.
Discussion
With the development of recombinant DNA technique, the 
therapeutic use of GH is expanding not only to patients with 
GH-deficient short stature but also to children with non-GH-
deficient short stature
1, 2). Children with short stature are treated 
with GH under the assumption that there is no interference of 
GH treatment on the timing of puberty. However, the effect of 
GH therapy on pubertal onset and bone maturation of children 
remains controversial. Low dose GH
6) and medium dose GH 
treatment
7) had no effect on pubertal onset or pace. On the other 
hand, some studies suggest that GH treatment may induce an early 
onset of puberty and accelerated skeletal maturation. High dose 
GH treatment was associated with acceleration of pubertal onset 
and bone maturation
8). Kaplowitz
23) and Kawai et al.
9)  reported 
that GH therapy for boys did not have a beneficial effect on their 
final height because bone maturation was accelerated during GH 
therapy.
There have been reports on the role of GH in the control of 
reproductive functions and the initiation of puberty. Firstly, GH 
might exert a direct effect on the ovaries. GH receptor mRNA 
Fig. 2. rhGH induced no change in the holding current of GnRH neurons. 
(A) Voltage-clamp recording of a GnRH neuron (postnatal day 21) 
holding at -60 mV showing no response to applied rhGH. (B) Amplitudes 
of postsynaptic currents were truncated to better depict changes in 
holding current. (C) A cumulative distribution graph of amplitude and 
IEE before, on, and after rhGH application, was obtained from the same 
cell as in A. (D), (E) A cumulative bar graph showing frequency before 
(1.93±0.69), on (1.88±0.68), and after (1.74±0.52), and amplitude 
before (46.8±0.56), on (47.8±0.60), and after (47.1±0.60), application 
of postsynaptic currents from 7 immature GnRH neurons. No significant 
difference was found in the frequency and amplitude before, on, and 
after rhGH application. (F) Application of 300 nM somatostatin induced 
an outward shift in holding current on GnRH neuron (postnatal day 21).
Abbreviations: Cont, control; IEE, inter-event interval; rhGH, recombinant 
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expression and GH binding protein (GHBP) been detected in 
the ovaries in humans
24), and in several animal species
25-29). GH 
treatment augments the follicle-stimulating hormone (FSH)-
induced differentiation of ovarian granulosa cells
30). Furthermore 
GH, in the absence of FSH, can induce folliculogenesis in isolated 
ovarian preantral follicles of immature mice, strongly suggesting 
a role of GH in the control of ovarian function
31). In male rats, the 
experimental induction of GH deficiency is associated with the 
delay in testicular growth and the differentiation of the germ cells 
11). Secondly, GH has an effect on gonadotropes in the pituitary 
gland. Plasma LH response to GnRH treatment was significantly 
attenuated in GH receptor gene knockout mice
13). GH-treated 
monkeys have an earlier initial rise in serum LH concentrations 
and secrete significantly higher amounts of estradiol compared 
to non-treated monkeys
32). GH antigens are present in pituitary 
cells containing FSH or LH mRNAs and in cells containing 
GnRH receptors indicating that either GH cells are transitory 
gonadotrophs, or GH is present in these pituitary cells most likely 
assisting to control their function
33, 34). In addition, GH-binding 
protein antigens were identified in pituitary cells that contained LH 
and FSH, indicating a possible paracrine effect of GH in the control 
of the gonadotrope functions
35). Therefore, GH may function as a 
“co-gonadotropin”
36). Thirdly, GH has an indirect effect via IGF-I 
on the ovary and GnRH neuron. Patients with Laron syndrome 
are infertile and it has been demonstrated that administration of 
IGF-I initiates puberty in these subjects
14). It has been shown in 
prepubertal female rats that IGF-I increases GnRH release
16). It is 
known that in addition to being derived from the peripheral origin, 
IGF-I is synthesized within the hypothalamus and the pituitary 
gland, and there is evidence for the presence of its receptors in the 
hypothalamus and the pituitary gland
16). In vitro studies have 
revealed that IGF-I increases GnRH-induced gonadotropin 
secretion by the pituitary cells
15). Zhen et al.
17) demonstrated the 
expression of IGF-I receptors on GnRH neuronal cell line, and 
activation of GnRH mRNA expression and GnRH neuronal cell 
proliferation can be induced by IGF-I. 
Recently, the effects of GH on the central nervous system 
(CNS) have received much attention. In humans, GH receptors 
are found in most areas of the CNS. They are detected in 
their highest concentrations in the choroid plexus, but are also 
found in the hippocampus, putamen, thalamus, pituitary and 
hypothalamus
37-39). The GH receptor mRNA has also been 
detected in samples of human fronto-parietal and temporal 
cortex
40). There are some reports that support the ability of GH to 
cross the blood brain barrier (BBB). In acromegalic patients with 
excessive GH levels in their plasma, some researchers have found 
normal GH levels in the cerebrospinal fluid (CSF)
41), whereas others 
have found increased levels
42). When GH is applied externally for 
GH substitution, there is an increase in GH levels in the CSF
43, 44). 
In conformity with insulin and leptin, GH has been suggested to 
reach its responsive sites in the brain following a receptor-mediated 
transport across the BBB
45, 46). Among all the effects exerted by 
GH on brain function, some may result from a direct action of the 
hormone on its brain receptors, whereas other effects elicited by the 
hormone may be due to GH-induced mediator-insulin-like growth 
factor-I (IGF-I). There have been some studies on the effects of 
IGF-I on GnRH neurons. 
This study was undertaken to determine the direct effects of 
GH on GnRH neurons, key regulator of the reproductive system. 
Since GnRH neurons are distributed sparsely throughout the 
hypothalamus, the studying of living GnRH neurons has been 
complicated. With the development of transgenic mice in which 
green fluorescent protein is genetically targeted to GnRH neurons, 
studies of living GnRH neurons have been facilitated
47). We 
performed a gramicidin-perforated patch- clamp study to elucidate 
the effect of rhGH on electrical activities of GnRH neurons. 
Gramicidin forms pores only permeable to monovalent cations
48) 
and keeps the concentration of intracellular chloride unchanged by 
the pipette solution, and further preventing washout of intracellular 
factors that can be important for a second messenger system. Using 
perforated patched-clamp recordings, Han et al. demonstrated that 
GnRH exerts depolarizing actions on the excitability of GnRH 
neurons
49) and kisspeptin evokes long-lasting depolarization of 
GnRH neurons in adult mice
50).
Our findings demonstrate that 1) in gramicidin-perforated 
current clamp mode, the majority of GnRH neuron tested did not 
show any response to applied rhGH in varying concentrations; 
and 2) in whole-cell voltage-clamp mode, there was no significant 
change in holding current and postsynaptic currents. These results 
indicate that rhGH does not directly affect the excitability of 
GnRH neurons.
We tested limited numbers (n=29) of GnRH neurons which is a 
small population to represent whole GnRH neurons, and thus it is 
haste to conclude that rhGH has no influence on GnRH neurons. 
Since GnRH neurons are suppressed during childhood and 
activated with the onset of puberty, electrophysiological activities 
of GnRH neurons also may also be different according to the 
developmental stage. Since we examined the acute effects of rhGH 
administration on the electrical excitability of GnRH neurons, it is 
difficult to compare the impact of rhGH on pubertal acceleration 
in human beings. Further work with large numbers of GnRH 
neurons and variety concentration of rhGH is required to reconcile 850      JP Bhattarai, et al. • Patch clamp study of rhGH on GnRH neurons
our findings and to determine the effect of rhGH on hypothalamic 
GnRH neurons.
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